Dr Gillon joined DNDi as Head of Translation in August 2016 and is responsible for advancing the development of new investigational drugs from preclinical research to early clinical development.
Dr Gillon most recently served as Director of Drug Development at Innovative Medicines For Tuberculosis (iM4TB), a spin-off of the Swiss Federal Polytechnic Institute (EPFL) in Lausanne. He has over 15 years of pharmaceutical industry experience gained in R&D and portfolio management roles, including with PregLem in 2012-2013, Merck-Serono from 2007 to 2011 and Serono from 2001 to 2007 where he led the preclinical and early development of several new therapeutics for the treatment of auto-immune diseases and cancer. Prior to this and during 10 years, he held various positions with increasing responsibilities in life science CROs (Battelle Memorial Institute, Neurotech and MDS).
Dr Gillon graduated in 1986 as PharmD from Claude Bernard University in Lyon and he was awarded his PhD in Neurosciences in 1989, also from Claude Bernard University, Lyon.